SRR12475163
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.450
- MYC_TARGETS_V1+0.430
- G2M_CHECKPOINT+0.400
- FATTY_ACID_METABOLISM+0.390
- CHOLESTEROL_HOMEOSTASIS+0.360
- MTORC1_SIGNALING+0.350
- PEROXISOME+0.350
- OXIDATIVE_PHOSPHORYLATION+0.320
- MYC_TARGETS_V2+0.280
- PI3K_AKT_MTOR_SIGNALING+0.250
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.330
- MYOGENESIS-0.300
- TGF_BETA_SIGNALING-0.300
- APICAL_SURFACE-0.290
- TNFA_SIGNALING_VIA_NFKB-0.270
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.260
- HYPOXIA-0.220
- KRAS_SIGNALING_DN-0.210
- PANCREAS_BETA_CELLS-0.180
- UV_RESPONSE_DN-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A8-A09W-01A-11R-A00Z-07 | — | B | 0.871 |
| 2 | 77984740-019e-482f-822a-25a74ec2cc32 | — | — | 0.866 |
| 3 | TCGA-66-2727-01A-01R-0980-07 | — | cohortSQ2 | 0.845 |
| 4 | BS_W80TJC27 | Supratentorial Ependymoma | — | 0.845 |
| 5 | SRR17866821 | — | — | 0.844 |
| 6 | TCGA-60-2706-01A-01R-0851-07 | — | cohortA4 | 0.839 |
| 7 | MNG477 | — | — | 0.832 |
| 8 | 3fca0833-b19b-47af-b75e-c9c45a99373b | — | — | 0.831 |
| 9 | TCGA-95-7562-01A-11R-2241-07 | — | cohortA4 | 0.826 |
| 10 | 81b828aa-cb06-4790-ba3e-efaa39f4eeef | — | — | 0.825 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.450 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.430 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.390 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.360 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.350 | Inavolisib | — uncovered |
| PEROXISOME | 0.350 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.320 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.280 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.250 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.250 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.240 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.240 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.240 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.190 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.160 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.160 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.150 | Idelalisib | — uncovered |